Adakveo
Generic name: crizanlizumab-tmca
Dosage form: Injection, for intravenous use
Drug class: Miscellaneous uncategorized agents
Approval date: November 15, 2019
Company: Novartis Pharmaceuticals Corporation
Treatment for: Pain Crises in Sickle Cell Disease
Patient Information
Read this Patient Information before you start treatment. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
What is Adakveo?
Adakveo is used:
- in people 16 years of age and older who have sickle cell disease
- to help reduce how often certain episodes (crises) happen.
It is not known if Adakveo is safe and effective in children under 16 years of age.
Warnings
Adakveo may cause serious side effects, including:
Infusion reactions. Infusion reactions may happen within 24 hours of receiving an infusion of Adakveo. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infusion reaction:
- fever
- chills or shivering
- nausea
- vomiting
- tiredness
- dizziness
- sweating
- hives
- itching
- shortness of breath or wheezing
Your healthcare provider may monitor you for signs and symptoms of infusion reactions.
Adakveo may interfere with a certain blood test.
Tell your healthcare providers that you are receiving Adakveo before having any blood tests. Adakveo may interfere with a laboratory test to measure your platelet counts.
See Adakveo side effects for more information about side effects.
Before receiving Adakveo
Before you receive Adakveo, tell your healthcare provider about all of your medical conditions, including if you:
- are pregnant or plan to become pregnant. It is not known if Adakveo may harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if Adakveo passes into your breast milk. You and your healthcare provider should decide the best way to feed your baby during treatment.
Tell your healthcare provider about all of the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements.
How will I receive Adakveo?
- Your healthcare provider will give you Adakveo as an infusion into your vein through an intravenous (IV) line over 30 minutes.
- You will receive your first infusion, and then a second infusion 2 weeks later. After that, you will receive an infusion every 4 weeks.
- Your healthcare provider may also prescribe other treatments for you to take during treatment.
- Do not stop receiving this medicine unless your healthcare provider tells you to.
- If you miss an appointment for infusion, call your healthcare provider as soon as possible to reschedule.
Adakveo side effects
Adakveo may cause serious side effects. See Important information.
The most common side effects include:
- nausea
- back pain
- joint pain
- fever
These are not all of the possible side effects. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Related/similar drugs
Hydrea
Hydrea is used for chronic myelogenous leukemia, head and neck cancer
Omvoh
Omvoh is used to treat moderate to severe ulcerative colitis or Crohn's disease in adults. This ...
Alpha E
Alpha E is used for alzheimer's disease, cystic fibrosis, dietary supplementation, nocturnal leg ...
Glutamine
Glutamine systemic is used for dietary supplementation, short bowel syndrome, sickle cell anemia
General information about the safe and effective use of Adakveo.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for more information.
What are the ingredients in Adakveo?
Active ingredient: crizanlizumab-tmca
Inactive ingredients: citric acid, polysorbate 80, sodium citrate, and water for injection
Adakveo Biosimilars
Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.
Reference products
These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for Adakveo.
Adakveo (crizanlizumab-tmca) - Novartis Pharmaceuticals Corporation
| Formulation type | Strength |
|---|---|
| Single-Dose Vial | 100 mg/10 mL (10 mg/mL) |
Popular FAQ
What type of drug is Adakveo and how does it work?
Adakveo injection is a targeted biologic P-selectin inhibitor that blocks interactions between certain blood cells and blood vessels to make them less “sticky”. This helps to reduce how often painful crises occur in patients with sickle cell disease. Continue reading
How is Adakveo administered?
Adakveo is administered by an intravenous (IV) infusion over 30 minutes. The correct dose of Adakveo for you will be mixed in a sterile IV bag containing 0.9% Sodium Chloride for injection or 5% Dextrose for injection and given directly into your vein via a small, hollow, plastic tube called a cannula. Adakveo cannot be self-administered at home, it must be prepared and administered by a health professional. Continue reading
More about Adakveo (crizanlizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous uncategorized agents
- Breastfeeding
- En español
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
